CompletedPhase 4NCT03731169

CYP2C19 Genotype-Specific Dosing Plus TDM on Reaching Therapeutic Voriconazole Blood Levels

Studying Aspergillosis

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
University Health Network, Toronto
Principal Investigator
Marisa Battistella, PharmD
University Health Network, Toronto
Intervention
Voriconazole genotype-specific dosing(genetic)
Enrollment
30 enrolled
Eligibility
18 years · All sexes
Timeline
20182020

Study locations (2)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT03731169 on ClinicalTrials.gov

Other trials for Aspergillosis

Additional recruiting or active studies for the same condition.

See all trials for Aspergillosis

← Back to all trials